Glutide for Ending Methamphetamine use
Official title: Glutide for Ending Methamphetamine
Funded at Public Health Foundation Enterprises · NIH-11399999 · Data updated 2026-11-12
A new treatment approach using GLP-1 based therapy aimed at helping adults reduce methamphetamine cravings and use.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Public Health Foundation Enterprises NIH-funded |
| Lab location | 1 site (City of Industry, United States) |
| Project start | September 1, 2025 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $862,498 |
| NIH project number | 5UG3DA063329-02 |
| Project ID | NIH-11399999 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults 21+ with methamphetamine use disorder who may benefit from GLP-1 pathway–targeted treatment.
✕Less likely to help
Individuals without methamphetamine use disorder or with contraindications to GLP-1 based therapy may not benefit.
What this research studies
This project focuses on adults 21 and older who struggle with methamphetamine use. Researchers plan to test GLP-1 related therapy, potentially in combination with other agents, to reduce cravings and support abstinence. The study will monitor safety, weight changes, and adherence, while exploring how this treatment fits into real-world care for methamphetamine use disorder.
Why it matters
Potential benefit: If successful, this approach could lessen cravings and help people achieve and maintain abstinence from methamphetamine.
How similar studies have gone: GLP-1 agonists have shown promise in reducing cravings in substance use disorders, suggesting potential applicability to methamphetamine use.
Where this research is happening
-
Public Health Foundation Enterprises
City of Industry, United States Active
Researchers
- Principal investigator: Coffin, Phillip O — Public Health Foundation Enterprises
- Study coordinator: Coffin, Phillip O
Related research
Other NIH-funded projects on the same topics.
-
San Francisco Bay Area HIV Clinical Trials Unit (CTU) led by top HIV prevention and treatment experts
A large HIV clinical trials program in the San Francisco Bay Area aims to speed prevention and treatment research for people at risk or living with HIV.
-
San Francisco Bay Area HIV Clinical Trials Unit for Prevention and Treatment
A local HIV clinical trials program led by top Bay Area researchers aims to speed up prevention and treatment studies through community-engaged research across ACTG, HPTN, and HVTN networks.
-
Behavioral safety and fentanyl education for people who use stimulants (BSAFE)
A patient-facing program adapts an overdose-prevention approach into a personalized plan plus text reminders to help people who use stimulants avoid unintentional fentanyl exposure.
-
Long-acting injectable HIV prevention for transgender and non-binary people
This project offers long‑acting injectable HIV prevention (cabotegravir) through a trans-affirming clinic to help transgender and non‑binary people use PrEP more easily.
-
Take Charge: Boosting PrEP awareness and support in the Deep South
This project helps people in the Deep South learn about, start, and stay on PrEP using social media, peer navigators, and mobile support tools.
-
San Francisco Bay Area HIV Clinical Trials Unit
Offers clinical trials of new HIV prevention and treatment approaches for people at risk for or living with HIV, especially men who have sex with men and people who inject drugs in the San Francisco Bay Area.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.